UPDATE: Stifel Starts DarioHealth Corp. (DRIO) at Buy
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
Stifel analyst David Grossman initiates coverage on DarioHealth Corp. (NASDAQ: DRIO) with a Buy rating and a price target of $30.00.
The analyst comments "While there are obvious financial and operating risks associated with being early, there are early signs they are successfully executing on their transition to the enterprise market. We believe continued success in making this transition will help validate their business model and lead to share gains, upward earnings revision and multiple expansion."
Shares of DarioHealth Corp. closed at $19.77 yesterday.
You May Also Be Interested In
- S&P Global (SPGI) PT Raised to $414 at Stifel, Raises Estimates
- UPDATE: Mizuho Securities Starts Ameren Corp (AEE) at Neutral (correction)
- Sonova Holding AG (SOON:SW) (SONVY) PT Raised to CHF217 at Goldman Sachs
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesStifel, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!